A phase II clinical trial was conducted to investigate GP2 vaccine efficacy in preventing recurrence in LN+ and high-risk LN- HER2 breast cancer patients (IHC 1+–3+) in the adjuvant setting. Here, GP2 is linked to breast cancer.